It’s not deflection.
You want the number of people dosed in the past two years to be the MOST important thing that’s happening with MSCs. It simply isn’t now that 4 x P3 trials have been done with the FDA.
If the 4 x P3s hadn’t been done I would agree with you.
Cynata is literally years and years behind now. And doesn’t have street cred.
And all the shareholders are stuck in quicksand.
Sculptor P3 OA trial recruitment has passed the halfway mark, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.010(6.45%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 16.5¢ | 15.5¢ | $35.20K | 219.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50171 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 70000 | 2 |
View Market Depth
| Last trade - 13.33pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |